Connectivity Map-based Discovery of Parbendazole Reveals Targetable Human Osteogenic Pathway

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2015 Oct 1

PMID 26420877

Citations 48

Authors

Andrea M Brum

Jeroen van de Peppel

Cindy S van der Leije

Marijke Schreuders-Koedam

Marco Eijken

Bram C J van der Eerden

Johannes P T M van Leeuwen

Affiliations

Soon will be listed here.

Abstract

Osteoporosis is a common skeletal disorder characterized by low bone mass leading to increased bone fragility and fracture susceptibility. In this study, we have identified pathways that stimulate differentiation of bone forming osteoblasts from human mesenchymal stromal cells (hMSCs). Gene expression profiling was performed in hMSCs differentiated toward osteoblasts (at 6 h). Significantly regulated genes were analyzed in silico, and the Connectivity Map (CMap) was used to identify candidate bone stimulatory compounds. The signature of parbendazole matches the expression changes observed for osteogenic hMSCs. Parbendazole stimulates osteoblast differentiation as indicated by increased alkaline phosphatase activity, mineralization, and up-regulation of bone marker genes (alkaline phosphatase/ALPL, osteopontin/SPP1, and bone sialoprotein II/IBSP) in a subset of the hMSC population resistant to the apoptotic effects of parbendazole. These osteogenic effects are independent of glucocorticoids because parbendazole does not up-regulate glucocorticoid receptor (GR) target genes and is not inhibited by the GR antagonist mifepristone. Parbendazole causes profound cytoskeletal changes including degradation of microtubules and increased focal adhesions. Stabilization of microtubules by pretreatment with Taxol inhibits osteoblast differentiation. Parbendazole up-regulates bone morphogenetic protein 2 (BMP-2) gene expression and activity. Cotreatment with the BMP-2 antagonist DMH1 limits, but does not block, parbendazole-induced mineralization. Using the CMap we have identified a previously unidentified lineage-specific, bone anabolic compound, parbendazole, which induces osteogenic differentiation through a combination of cytoskeletal changes and increased BMP-2 activity.

Citing Articles

Mechanism-free repurposing of drugs for C9orf72-related ALS/FTD using large-scale genomic data.

Saez-Atienzar S, Souza C, Chia R, Beal S, Lorenzini I, Huang R Cell Genom. 2024; 4(11):100679.

PMID: 39437787 PMC: 11605688. DOI: 10.1016/j.xgen.2024.100679.

Cancer pharmacoinformatics: Databases and analytical tools.

Kamble P, Nagar P, Bhakhar K, Garg P, Sobhia M, Naidu S Funct Integr Genomics. 2024; 24(5):166.

PMID: 39294509 DOI: 10.1007/s10142-024-01445-5.

A cellular senescence-related signature for predicting prognosis, immunotherapy response, and candidate drugs in patients treated with transarterial chemoembolization (TACE).

He N, Zhao W, Tian W, Wu Y, Xu J, Lu Y Discov Oncol. 2024; 15(1):271.

PMID: 38976093 PMC: 11231123. DOI: 10.1007/s12672-024-01116-8.

The Potential of a Stratified Approach to Drug Repurposing in Alzheimer's Disease.

Anderson C, Bucholc M, McClean P, Zhang S Biomolecules. 2024; 14(1).

PMID: 38275752 PMC: 10813465. DOI: 10.3390/biom14010011.

Repurposing fluphenazine as an autophagy modulator for treating liver cancer.

Su C, Cheng C, Rong Z, Yang J, Li Z, Yao J Heliyon. 2023; 9(12):e22605.

PMID: 38107270 PMC: 10724577. DOI: 10.1016/j.heliyon.2023.e22605.

References

McBeath R, Pirone D, Nelson C, Bhadriraju K, Chen C . Cell shape, cytoskeletal tension, and RhoA regulate stem cell lineage commitment. Dev Cell. 2004; 6(4):483-95. DOI: 10.1016/s1534-5807(04)00075-9. View

Chang Y, Nalbant P, Birkenfeld J, Chang Z, Bokoch G . GEF-H1 couples nocodazole-induced microtubule disassembly to cell contractility via RhoA. Mol Biol Cell. 2008; 19(5):2147-53. PMC: 2366883. DOI: 10.1091/mbc.e07-12-1269. View

Qu X, Rajpal D . Applications of Connectivity Map in drug discovery and development. Drug Discov Today. 2012; 17(23-24):1289-98. DOI: 10.1016/j.drudis.2012.07.017. View

KAIGHN M, Narayan K, Ohnuki Y, Lechner J, Jones L . Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol. 1979; 17(1):16-23. View

Lavery K, Swain P, Falb D, Alaoui-Ismaili M . BMP-2/4 and BMP-6/7 differentially utilize cell surface receptors to induce osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells. J Biol Chem. 2008; 283(30):20948-58. PMC: 3258927. DOI: 10.1074/jbc.M800850200. View

Jordan M, Wilson L . Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004; 4(4):253-65. DOI: 10.1038/nrc1317. View

Lamb J, Crawford E, Peck D, Modell J, Blat I, Wrobel M . The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006; 313(5795):1929-35. DOI: 10.1126/science.1132939. View

Eijken M, Swagemakers S, Koedam M, Steenbergen C, Derkx P, Uitterlinden A . The activin A-follistatin system: potent regulator of human extracellular matrix mineralization. FASEB J. 2007; 21(11):2949-60. DOI: 10.1096/fj.07-8080com. View

Johnell O, Kanis J . An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006; 17(12):1726-33. DOI: 10.1007/s00198-006-0172-4. View

10.

Born A, Rottmar M, Lischer S, Pleskova M, Bruinink A, Maniura-Weber K . Correlating cell architecture with osteogenesis: first steps towards live single cell monitoring. Eur Cell Mater. 2009; 18:49-60, 61-2. DOI: 10.22203/ecm.v018a05. View

11.

Zhao M, Ko S, Liu J, Chen D, Zhang J, Wang B . Inhibition of microtubule assembly in osteoblasts stimulates bone morphogenetic protein 2 expression and bone formation through transcription factor Gli2. Mol Cell Biol. 2008; 29(5):1291-305. PMC: 2643819. DOI: 10.1128/MCB.01566-08. View

12.

Lecanda F, Avioli L, Cheng S . Regulation of bone matrix protein expression and induction of differentiation of human osteoblasts and human bone marrow stromal cells by bone morphogenetic protein-2. J Cell Biochem. 1997; 67(3):386-96. View

13.

Zhong Y, Chen E, Liu R, Chuang P, Mallipattu S, Tan C . Renoprotective effect of combined inhibition of angiotensin-converting enzyme and histone deacetylase. J Am Soc Nephrol. 2013; 24(5):801-11. PMC: 3636790. DOI: 10.1681/ASN.2012060590. View

14.

Kanis J, Johnell O . Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int. 2004; 16(3):229-38. DOI: 10.1007/s00198-004-1811-2. View

15.

Chiba H, Sawada N, Ono T, Ishii S, Mori M . Establishment and characterization of a simian virus 40-immortalized osteoblastic cell line from normal human bone. Jpn J Cancer Res. 1993; 84(3):290-7. PMC: 5919145. DOI: 10.1111/j.1349-7006.1993.tb02869.x. View

16.

Ingber D . Cellular mechanotransduction: putting all the pieces together again. FASEB J. 2006; 20(7):811-27. DOI: 10.1096/fj.05-5424rev. View

17.

Zilberberg L, Ten Dijke P, Sakai L, Rifkin D . A rapid and sensitive bioassay to measure bone morphogenetic protein activity. BMC Cell Biol. 2007; 8:41. PMC: 2094707. DOI: 10.1186/1471-2121-8-41. View

18.

Gazzerro E, Canalis E . Bone morphogenetic proteins and their antagonists. Rev Endocr Metab Disord. 2006; 7(1-2):51-65. DOI: 10.1007/s11154-006-9000-6. View

19.

Mathieu P, Loboa E . Cytoskeletal and focal adhesion influences on mesenchymal stem cell shape, mechanical properties, and differentiation down osteogenic, adipogenic, and chondrogenic pathways. Tissue Eng Part B Rev. 2012; 18(6):436-44. PMC: 3495119. DOI: 10.1089/ten.TEB.2012.0014. View

20.

Biggs M, Geoff Richards R, Dalby M . Nanotopographical modification: a regulator of cellular function through focal adhesions. Nanomedicine. 2010; 6(5):619-33. PMC: 2965469. DOI: 10.1016/j.nano.2010.01.009. View